DOCSLIB.ORG

Prescription Drug List Changes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prescription Drug List Changes PRESCRIPTION DRUG LIST CHANGES Cigna Pharmacy Management® 2021 To help make sure you have access to coverage for safe, clinically effective and low-cost medications, we regularly review and update the Cigna Prescription Drug List. You can see a list of these changes below. Changes are listed by drug list name, the date the change starts and by the type of change that’s taking place. Medications are then listed alphabetically by drug class. If you have Cigna-administered pharmacy benefits and you’re affected by one of these changes, we’ll send you a letter with specific information on next steps. STANDARD PRESCRIPTION DRUG LIST Start date of Drug class Medications moving to preferred brand change*,** June 22, 2021 PAIN RELIEF AND INFLAMMATORY DISEASE Reditrex May 15, 2021 EYE CONDITIONS Eysuvis GASTROINTESTINAL/HEARTBURN Sutab January 1, 2021 AIDS/HIV Juluca ASTHMA/COPD/RESPIRATORY Bevespi DIABETES Baqsimi GASTROINTESTINAL/HEARTBURN Pancreaze INFECTIONS Epclusa, Harvoni PAIN RELIEF AND INFLAMMATORY DISEASE Taltz Start date of Medications becoming Generic and/or preferred Drug class change*,** non-preferred brand brand alternatives June 29, 2021 BLOOD PRESSURE/HEART MEDICATIONS Orladeyo1 Lupron Depot June 22, 2021 CANCER Orgovyx1 No preferred formulary drug alternatives. June 15, 2021 GASTROINTESTINAL/HEARTBURN Lubiprostone 8 mcg, 24 mcg capsule Amitiza June 1, 2021 SKIN CONDITIONS Winlevi 1% cream Generic products (e.g. adapalene; tretinoin; clindamycin-benzoyl peroxide) Wynzora 0.005%-0.064% cream betamethasone DP, fluocinolone, fluticasone, mometasone, trimacinolone, calcipotriene, calcipotriene-betamethasone DP Generic medications start with a lowercase letter and brand name medications start with a capital letter. 951712 UPDATED_05/21/2021 STANDARD PRESCRIPTION DRUG LIST (cont) Start date of Medications becoming Generic and/or preferred Drug class change*,** non-preferred brand brand alternatives June 1, 2021 URINARY TRACT CONDITIONS Vesicare LS 5 mg/5 mL suspension oxybutynin chloride, oxybutynin chloride ER, darifenacin ER, solifenacin, tolterodine, tolterodine ER, tropsium May 15, 2021 EYE CONDITIONS Lacrisert Restasis, Restasis Multi-dose, Xiidra May 2, 2021 PAIN RELIEF AND INFLAMMATORY DISEASE Qdolo tramadol May 1, 2021 SKIN PREPS Impeklo topical betamethasone dipropionate (augmented) 0.05%, clobetasol propionate 0.05%, halobetasol propionate 0.05%, fluocinolide 0.1% April 18, 2021 HORMONAL AGENTS Alkindi Sprinkle hydrocortisone 5mg tablet March 28, 2021 BLOOD PRESSURE/HEART MEDICATIONS Conjupri amlodipine, felodipine, nifedipine, nicardipine January 1, 2021 AIDS/HIV Intelence1 Talk to your doctor about other alternatives BLOOD MODIFIERS/BLEEDING DISORDERS Amicar 0.25 g/ml oral solution1 aminocaproic acid 0.25g/ml oral solution BLOOD PRESSURE/HEART MEDICATIONS Multaq, Norpace CR 150mg Talk to your doctor about other alternatives CANCER Tabloid Talk to your doctor about other alternatives ERECTILE DYSFUNCTION Caverject Impulse Syringe MUSE EYE CONDITIONS Lotemax 0.5% drops loteprednol 0.5% drops HORMONAL AGENTS Armour Thyroid, Synthroid, Unithroid levothyroxine INFECTIONS Kitabis Pak1 tobramycin pak 300mg/5ml SEIZURE DISORDERS Lyrica 20mg/ml oral solution pregabalin 20mg/ml oral solution SUBSTANCE ABUSE Bunavail buprenorphine/naloxone film or sublingual tablet, Zubsolv WEIGHT MANAGEMENT Megace ES 625mg/5ml oral suspension megestrol 625ml/5ml oral suspension Start date of Drug class Medications that will need approval (prior authorization)^ change*,** June 29, 2021 BLOOD PRESSURE/HEART MEDICATIONS Orladeyo1 June 22, 2021 PAIN RELIEF AND INFLAMMATORY DISEASE Reditrex June 1, 2021 ASTHMA/COPD/RESPIRATORY Zokinvy March 14, 2021 CANCER Gavreto January 1, 2021 BLOOD THINNERS/ANTI-CLOTTING Eliquis4, Pradaxa4, Savaysa4, Xarelto4 PAIN RELIEF AND INFLAMMATORY DISEASE diclofenac 1.3% patch, Flector 1.3% patch5, Voltaren 1% gel5 Start date of Drug class Medications that will have a quantity limit change*,** June 29, 2021 BLOOD PRESSURE/HEART MEDICATIONS Orladeyo1 June 1, 2021 ASTHMA/COPD/RESPIRATORY Zokinvy May 15, 2021 EYE CONDITIONS Eysuvis May 2, 2021 PAIN RELIEF AND INFLAMMATORY DISEASE Qdolo Generic medications start with a lowercase letter and brand name medications start with a capital letter. STANDARD PRESCRIPTION DRUG LIST (cont) Start date of Drug class Medications that will have a quantity limit change*,** March 14, 2021 CANCER Gavreto Start date of Medications that will no longer Generic and/or preferred Drug class change*,** be covered^^ brand alternatives June 29, 2021 SKIN CONDITIONS Klisyri topical fluorouracil, imiquimod 5% cream June 22, 2021 GASTROINTESTINAL/HEARTBURN Reltone ursodiol HORMONAL AGENTS Thyquidity levothyroxine, levoxyl, Levo-T, Unithroid, Euthyrox June 15, 2021 GASTROINTESTINAL/HEARTBURN Lubiprostone 8 mcg, 24 mcg capsule Amitiza June 1, 2021 SKIN CONDITIONS Winlevi 1% cream Generic products (e.g. adapalene; tretinoin; clindamycin-benzoyl peroxide) June 1, 2021 SKIN CONDITIONS (cont) Wynzora 0.005%-0.064% cream betamethasone DP, fluocinolone, fluticasone, mometasone, trimacinolone, calcipotriene, calcipotriene-betamethasone DP URINARY TRACT CONDITIONS Vesicare LS 5 mg/5 mL suspension oxybutynin chloride, oxybutynin chloride ER, darifenacin ER, solifenacin, tolterodine, tolterodine ER, tropsium May 2, 2021 PAIN RELIEF AND INFLAMMATORY DISEASE Qdolo tramadol May 1, 2021 SKIN PREPS Impeklo topical betamethasone dipropionate (augmented) 0.05%, clobetasol propionate 0.05%, halobetasol propionate 0.05%, fluocinolide 0.1% April 18, 2021 HORMONAL AGENTS Alkindi Sprinkle hydrocortisone 5mg tablet March 28, 2021 BLOOD PRESSURE/HEART MEDICATIONS Conjupri amlodipine, felodipine, nifedipine, nicardipine January 1, 2021 ASTHMA/COPD/RESPIRATORY ProAir HFA7, ProAir RespiClick7, albuterol HFA Ventolin HFA7 DIABETES Kombiglyze XR8, Onglyza8 metformin, Janumet, Janumet XR, Januvia EYE CONDITIONS Lumigan7, Travatan Z, Xalatan, Xelpros, bimatoprost, latanoprost, travoprost Zioptan9 GASTROINTESTINAL/HEARTBURN Creon7, Pertzye, Zenpep7 Pancreaze Motegrity, Trulance7, Zelnorm Amitiza, Linzess Sensipar cinacalcet HORMONAL AGENTS TaperDex dexamethasone 1.5mg tablet INFECTIONS Baraclude entecavir tablet Noxafil tablet posaconazole DR 100mg tablet MULTIPLE SCLEROSIS Ampyra ER7 dalfampridine ER NUTRITIONAL/DIETARY PreGenna, Trinaz Any generic prenatal vitamin PAIN RELIEF AND INFLAMMATORY DISEASE Amerge generic triptans (e.g. naratriptan; sumatriptan) Generic medications start with a lowercase letter and brand name medications start with a capital letter. STANDARDStart date of PRESCRIPTION DRUG LISTMedications (cont) that will no longer Generic and/or preferred Drug class change*,** be covered^^ brand alternatives January 1, 2021 PAIN RELIEF AND INFLAMMATORY DISEASE butalbital-acetaminophen 50-300mg tablet butalbutal-acetaminophen 50-325mg tablet Cosentyx10 Enbrel, Humira, Otezla, Skyrizi, Stelara, Taltz Frova, Maxalt, Maxalt MLT, Relpax generic triptans (e.g. naratriptan; sumatriptan) SEIZURE DISORDERS Felbatol11 felbamate Keppra/Keppra XR11 levetiracetam/levetiracetam ER Lamictal XR Start Kit11 lamotrigine ER Lamictal/ODT/XR11 lamotrigine, lamotrigine ER, lamotrigine ODT Qudexy XR11, Trokendi XR11 topiramate ER Sabril11 vigabatrin, vigadrone Topamax11 topiramate Trileptal11 oxcarbazepine Zonegran11 zonisamide SKIN CONDITIONS Apexicon E5, diflorasone, Impoyz5, Olux5, betamethasone, clobetasol, halobetasol Olux-E5, psorcon Condylox imiquimod 5% cream packet, podofilox 0.5% topical solution Cordran5 betamethasone, clobetasol, fluocinolone, fluticasone, halobetasol Finacea Foam7, Finacea Gel, MetroCream, azelaic acid, topical metronidazole MetroGel, MetroLotion, Soolantra12 flurandrenolide, hydrocortisone butyrate betamethasone, fluocinolone, fluticasone lipid cream, lotion5, Pandel5 Sorilux calcitriol, tazarotene, topical calcipotriene Tridesilon5 alclometasone, desonide, triamcinolone Xolegel ciclopirox 0.77% gel, ciclopirox 1% shampoo, ketoconazole 2% cream, ketoconazole 2% foam, selenium 2.5% lotion, sodium sulfacetamide 10% shampoo SLEEP DISORDERS/SEDATIVES Belsomra8 Dayvigo URINARY TRACT CONDITIONS Procysbi4 Cystagon Start date of Medications that will be Drug class Additional information change*,** excluded from coverage January 1, 2021 SKIN CONDITIONS Rosadan Kits azelaic acid, topical metronidazole Generic medications start with a lowercase letter and brand name medications start with a capital letter. VALUE PRESCRIPTION DRUG LIST Start date of Drug class Medications moving to preferred brand change*,** June 22, 2021 PAIN RELIEF AND INFLAMMATORY DISEASE Reditrex May 15, 2021 EYE CONDITIONS Eysuvis GASTROINTESTINAL/HEARTBURN Sutab January 1, 2021 AIDS/HIV Juluca DIABETES Baqsimi GASTROINTESTINAL/HEARTBURN Pancreaze INFECTIONS Epclusa, Harvoni PAIN RELIEF AND INFLAMMATORY DISEASE Ajovy13, Emgality13, Taltz SEIZURE DISORDERS Vimpat URINARY TRACT CONDITIONS Cystagon Start date of Medications becoming Generic and/or preferred Drug class change*,** non-preferred brand brand alternatives June 29, 2021 BLOOD PRESSURE/HEART MEDICATIONS Orladeyo1 No preferred formulary drug alternatives June 22, 2021 CANCER Orgovyx1 Lupron Depot June 15, 2021 GASTROINTESTINAL/HEARTBURN Lubiprostone 8 mcg, 24 mcg capsule Amitiza June 1, 2021 SKIN CONDITIONS Winlevi 1% cream Generic products (e.g. adapalene; tretinoin; clindamycin-benzoyl peroxide) Wynzora 0.005%-0.064% cream betamethasone DP, fluocinolone, fluticasone, mometasone, trimacinolone, calcipotriene, calcipotriene-betamethasone DP URINARY TRACT CONDITIONS Vesicare LS 5 mg/5 mL suspension
Load more

Recommended publications
  • Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review
    Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review (TCR) March 7, 2019 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. March 2019 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004–2019 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) alosetron (Lotronex®)1 generic, .
    [Show full text]
  • Trihydroxyisoflavone Improves Skin Barrier Function Impaired by E
    www.nature.com/scientificreports OPEN A novel mineralocorticoid receptor antagonist, 7,3’,4’‑trihydroxyisofavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids Hanil Lee1,5, Eun‑Jeong Choi2,5, Eun Jung Kim1, Eui Dong Son2, Hyoung‑June Kim2, Won‑Seok Park2, Young‑Gyu Kang2, Kyong‑Oh Shin3, Kyungho Park3, Jin‑Chul Kim4, Su‑Nam Kim4 & Eung Ho Choi1* Excess glucocorticoids (GCs) with either endogenous or exogenous origins deteriorate skin barrier function. GCs bind to mineralocorticoid and GC receptors (MRs and GRs) in normal human epidermal keratinocytes (NHEKs). Inappropriate MR activation by GCs mediates various GC‑induced cutaneous adverse events. We examined whether MR antagonists can ameliorate GC‑mediated skin barrier dysfunction in NHEKs, reconstructed human epidermis (RHE), and subjects under psychological stress (PS). In a preliminary clinical investigation, topical MR antagonists improved skin barrier function in topical GC‑treated subjects. In NHEKs, cortisol induced nuclear translocation of GR and MR, and GR and MR antagonists inhibited cortisol‑induced reductions of keratinocyte diferentiation. We identifed 7,3’,4’‑trihydroxyisofavone (7,3’,4’‑THIF) as a novel compound that inhibits MR transcriptional activity by screening 30 cosmetic compounds. 7,3’,4’‑THIF ameliorated the cortisol efect which decreases keratinocyte diferentiation in NHEKs and RHE. In a clinical study on PS subjects, 7,3’,4’‑ THIF (0.1%)‑containing cream improved skin barrier function, including skin surface pH, barrier recovery rate, and stratum corneum lipids. In conclusion, skin barrier dysfunction owing to excess GC is mediated by MR and GR; thus, it could be prevented by treatment with MR antagonists. Therefore, topical MR antagonists are a promising therapeutic option for skin barrier dysfunction after topical GC treatment or PS.
    [Show full text]
  • Inflammatory Bowel Disease Irritable Bowel Syndrome
    Inflammatory Bowel Disease and Irritable Bowel Syndrome Similarities and Differences 2 www.ccfa.org IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 Important Differences Between IBD and IBS Many diseases and conditions can affect the gastrointestinal (GI) tract, which is part of the digestive system and includes the esophagus, stomach, small intestine and large intestine. These diseases and conditions include inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 www.ccfa.org 3 Inflammatory bowel diseases are a group of inflammatory conditions in which the body’s own immune system attacks parts of the digestive system. Inflammatory Bowel Disease Inflammatory bowel diseases are a group of inflamma- Causes tory conditions in which the body’s own immune system attacks parts of the digestive system. The two most com- The exact cause of IBD remains unknown. Researchers mon inflammatory bowel diseases are Crohn’s disease believe that a combination of four factors lead to IBD: a (CD) and ulcerative colitis (UC). IBD affects as many as 1.4 genetic component, an environmental trigger, an imbal- million Americans, most of whom are diagnosed before ance of intestinal bacteria and an inappropriate reaction age 35. There is no cure for IBD but there are treatments to from the immune system. Immune cells normally protect reduce and control the symptoms of the disease. the body from infection, but in people with IBD, the immune system mistakes harmless substances in the CD and UC cause chronic inflammation of the GI tract. CD intestine for foreign substances and launches an attack, can affect any part of the GI tract, but frequently affects the resulting in inflammation.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Pre Feasibility Report for Manufacturing of Apis
    Pre Feasibility Report For Manufacturing of APIs Cipla Limited Plot No. M12 & M14, Misc. Zone, Phase II, Sector III, Indore SEZ, Pithampur, District Dhar (M.P). - 454775 1 1. IDENTIFICATION OF PROJECT AND PROJECT PROPONENT: CIPLA Ltd is established in the year 1935 as a listed Public Limited Company. CIPLA is engaged in manufacturing of Bulk Drugs and Formulations of wide range of products in the form of tablets, injections, inhalers, capsules, ointment, powder, topical preparations, liquid, syrup drops, sprays, gels, suppositories etc. The company is having its registered office at Mumbai Central, Mumbai – 400 008. 80 years later, the company has become a front runner in the pharmaceutical industry, wielding the latest technology to combat disease and suffering in many ways, touching the lives of thousands the world over.The company’s products are manufactured in 25 state-of- art units. The company is having its manufacturing facilities at following locations: Locations Product Category Vikhroli- Mumbai R&D Virgonagar (Bangalore) Bulk Drugs and Formulations Bommasandra (Bangalore) Bulk Drug Patalganga Bulk Drugs and Formulations Kurkumbh Bulk Drugs and Formulations Goa Formulations Baddi Formulations Sikkim Formulations Indore Formulations The company is having well defined board of directors followed by managerial and technical team looking after entire operation. Management Council- 1. Mr. Umang Vohra - Managing Director and Global Chief Executive Officer 2. Mr. PrabirJha - Global Chief People Officer 3. Mr. KedarUpadhye - Global Chief Financial Officer 4. Dr. Ranjana Pathak - Global Head – Quality 5. Geena Malhotra - Global Head - Integrated Product Development 6. Mr. Raju Subramanyam – Global Head - Operations List of Key Executives- 1.
    [Show full text]
  • Therapeutic Class Overview Irritable Bowel Syndrome Agents
    Therapeutic Class Overview Irritable Bowel Syndrome Agents Therapeutic Class Overview/Summary: This review will focus on agents used for the treatment of Irritable Bowel Syndrome (IBS).1-5 IBS is a gastrointestinal syndrome characterized primarily by non-specific chronic abdominal pain, usually described as a cramp-like sensation, and abnormal bowel habits, either constipation or diarrhea, in which there is no organic cause. Other common gastrointestinal symptoms may include gastroesophageal reflux, dysphagia, early satiety, intermittent dyspepsia and nausea. Patients may also experience a wide range of non-gastrointestinal symptoms. Some notable examples include sexual dysfunction, dysmenorrhea, dyspareunia, increased urinary frequency/urgency and fibromyalgia-like symptoms.6 IBS is defined by one of four subtypes. IBS with constipation (IBS-C) is the presence of hard or lumpy stools with ≥25% of bowel movements and loose or watery stools with <25% of bowel movements. When IBS is associated with diarrhea (IBS-D) loose or watery stools are present with ≥25% of bowel movements and hard or lumpy stools are present with <25% of bowel movements. Mixed IBS (IBS-M) is defined as the presence of hard or lumpy stools with ≥25% and loose or water stools with ≥25% of bowel movements. Final subtype, or unsubtyped, is all other cases of IBS that do not fall into the other classes. Pharmacological therapy for IBS depends on subtype.7 While several over-the-counter or off-label prescription agents are used for the treatment of IBS, there are currently only two agents approved by the Food and Drug Administration (FDA) for the treatment of IBS-C and three agents approved by the FDA for IBS-D.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Formulary Updates Effective January 1, 2021
    Formulary Updates Effective January 1, 2021 Dear Valued Client, Please see the following lists of formulary updates that will apply to the HometownRx Formulary effective January 1 st , 2021. As the competition among clinically similar products increases, our formulary strategy enables us to prefer safe, proven medication alternatives and lower costs without negatively impacting member choice or access. Please note: Not all drugs listed may be covered under your prescription drug benefit. Certain drugs may have specific restrictions or special copay requirements depending on your plan. The formulary alternatives listed are examples of selected alternatives that are on the formulary. Other alternatives may be available. Members on a medication that will no longer be covered may want to talk to their healthcare providers about other options. Medications that do not have alternatives will be available at 100% member coinsurance . Preferred to Non -Preferred Tier Drug Disease State /Drug Class Preferred Alternatives ALREX Eye inflammation loteprednol (generic for LOTEMAX) APRISO 1 Gastrointestinal agent mesalamine (generic for APRISO) BEPREVE Eye allergies azelastine (generic for OPTIVAR) CIPRODEX 1 Ear inflammation ciprofloxacin-dexamethasone (generic for CIPRODEX) COLCRYS 1 Gout colchicine (generic for COLCRYS) FIRST -LANSOPRAZOLE Gastrointestinal agent Over-the-counter lansoprazole without a prescription FIRST -MOUTHWASH BLM Mouth inflammation lidocaine 2% viscous solution (XYLOCAINE) LOTEMAX 1 Eye inflammation loteprednol etabonate (generic
    [Show full text]
  • Australian Public Assessment Report for Clobetasol Propionate
    Australian Public Assessment Report for Clobetasol propionate Proprietary Product Name: Clobex Sponsor: Galderma Australia Pty Ltd May 2013 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. • TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <http://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. • An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Amitiza (Lubiprostone) Capsule, 24 Mcg and 8 Mcg
    CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: NDA 021908/S-010 Trade Name: AMITIZA Generic Name: Lubiprostonel Sponsor: Sucampo Pharma Americas, Inc. Approval Date: 11/26/2012 Indications: Amitiza is a chloride channel activator indicated for: Treatment of chronic idiopathic constipation in adults (1.1) Treatment of irritable bowel syndrome with constipation in women ≥ 18 years old (1.2) CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: NDA 021908/S-010 CONTENTS Reviews / Information Included in this NDA Review. Approval Letter X Other Action Letters Labeling X Summary Review Officer/Employee List Office Director Memo Cross Discipline Team Leader Review Medical Review(s) Chemistry Review(s) Environmental Assessment Pharmacology Review(s) X Statistical Review(s) Microbiology Review(s) Clinical Pharmacology/Biopharmaceutics Review(s) Risk Assessment and Risk Mitigation Review(s) Proprietary Name Review(s) Other Review(s) Administrative/Correspondence Document(s) X CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: NDA 021908/S-010 APPROVAL LETTER DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 21908/S-010 SUPPLEMENT APPROVAL Sucampo Pharma Americas, Inc. Attention: Jeff Carey Senior Director, Regulatory Affairs 4520 East-West Highway, Suite 300 Bethesda, Maryland 20814 Dear Mr. Carey: Please refer to your Supplemental New Drug Application (sNDA) dated and received March 7, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Amitiza (lubiprostone) Capsule, 24 mcg and 8 mcg. We acknowledge receipt of your amendment dated May 8, 2012. This Prior Approval supplemental new drug application provides for the following: • Removal of Section 5.1 Pregnancy • Revisions to Section 8.1 Pregnancy and Section 8.3 Nursing Mothers • Addition of Section 17.2 Nursing Mothers We have completed our review of this supplemental application, as amended.
    [Show full text]